JP2023539107A5 - - Google Patents
Info
- Publication number
- JP2023539107A5 JP2023539107A5 JP2023512094A JP2023512094A JP2023539107A5 JP 2023539107 A5 JP2023539107 A5 JP 2023539107A5 JP 2023512094 A JP2023512094 A JP 2023512094A JP 2023512094 A JP2023512094 A JP 2023512094A JP 2023539107 A5 JP2023539107 A5 JP 2023539107A5
- Authority
- JP
- Japan
- Prior art keywords
- activin
- antibody
- antigen
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068251P | 2020-08-20 | 2020-08-20 | |
| US63/068,251 | 2020-08-20 | ||
| US202063111394P | 2020-11-09 | 2020-11-09 | |
| US63/111,394 | 2020-11-09 | ||
| US202163139234P | 2021-01-19 | 2021-01-19 | |
| US63/139,234 | 2021-01-19 | ||
| PCT/US2021/046765 WO2022040461A1 (en) | 2020-08-20 | 2021-08-19 | Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539107A JP2023539107A (ja) | 2023-09-13 |
| JP2023539107A5 true JP2023539107A5 (enExample) | 2024-08-26 |
Family
ID=77774983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512094A Pending JP2023539107A (ja) | 2020-08-20 | 2021-08-19 | アクチビンａアンタゴニストによる心機能障害及びｃｏｖｉｄ－１９の予防及び治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220056119A1 (enExample) |
| EP (1) | EP4200017A1 (enExample) |
| JP (1) | JP2023539107A (enExample) |
| KR (1) | KR20230051683A (enExample) |
| CN (1) | CN116249713A (enExample) |
| AU (1) | AU2021327238A1 (enExample) |
| CA (1) | CA3189147A1 (enExample) |
| IL (1) | IL300362A (enExample) |
| MX (1) | MX2023001734A (enExample) |
| WO (1) | WO2022040461A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114397453B (zh) * | 2022-03-25 | 2022-06-07 | 江苏美克医学技术有限公司 | 新型冠状病毒突变株的检测试剂盒及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| PE20120532A1 (es) | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| CA2983440C (en) * | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| WO2018009732A1 (en) * | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| CA3052625A1 (en) * | 2017-02-06 | 2018-08-09 | Acceleron Pharma Inc. | Compositions and methods for treating heart failure |
| LT3600415T (lt) * | 2017-03-24 | 2025-12-29 | Novartis Ag | Antikūnas prieš ii tipo aktivino receptorių, skirtas naudoti širdies nepakankamumo gydymui |
| WO2019005963A1 (en) * | 2017-06-27 | 2019-01-03 | The University Of Chicago | USE OF ACTIVIN TO DETECT POST-PARTUM CARDIAC DYSFUNCTION |
-
2021
- 2021-08-19 JP JP2023512094A patent/JP2023539107A/ja active Pending
- 2021-08-19 MX MX2023001734A patent/MX2023001734A/es unknown
- 2021-08-19 CA CA3189147A patent/CA3189147A1/en active Pending
- 2021-08-19 AU AU2021327238A patent/AU2021327238A1/en active Pending
- 2021-08-19 CN CN202180063332.2A patent/CN116249713A/zh active Pending
- 2021-08-19 US US17/407,012 patent/US20220056119A1/en not_active Abandoned
- 2021-08-19 KR KR1020237008783A patent/KR20230051683A/ko active Pending
- 2021-08-19 EP EP21770348.7A patent/EP4200017A1/en active Pending
- 2021-08-19 WO PCT/US2021/046765 patent/WO2022040461A1/en not_active Ceased
- 2021-08-19 IL IL300362A patent/IL300362A/en unknown
-
2025
- 2025-05-22 US US19/216,288 patent/US20250277021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535948A5 (enExample) | ||
| JP2024150751A5 (enExample) | ||
| EP1680140B1 (en) | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof | |
| JP5734988B2 (ja) | Ｒｓｖ特異的結合分子 | |
| JP2010531890A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2006522830A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| ES2993153T3 (en) | Pan elr+ cxc chemokine antibodies | |
| JP2012504955A5 (enExample) | ||
| JP2009511480A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2019527194A5 (enExample) | ||
| JP2016094424A5 (enExample) | ||
| JP2019510739A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2025032102A5 (enExample) | ||
| JP7708860B2 (ja) | 呼吸器合胞体ウイルスに特異的に結合する分子 | |
| JP2018529635A5 (enExample) | ||
| JP2010501164A5 (enExample) | ||
| JP2013519367A5 (enExample) | ||
| WO2006110214A3 (en) | Antibodies against mammalian metapneumovirus | |
| JP2013508292A5 (enExample) |